Oramed Pharmaceuticals Inc
ORMP2.985USD
+0.055+1.88%
Market hours （ET）Quotes delayed by 15 min
121.90MMarket Cap
2.84P/E TTM
More Details of Oramed Pharmaceuticals Inc Company
Oramed Pharmaceuticals Inc. is a pharmaceutical company engaged in the research and development of pharmaceutical solutions with a technology platform. The Company has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.
Oramed Pharmaceuticals Inc Info
Ticker SymbolORMP
Company nameOramed Pharmaceuticals Inc
IPO dateApr 01, 2002
CEOKidron (Nadav)
Number of employees13
Security typeOrdinary Share
Fiscal year-endApr 01
Address1185 Avenue Of The Americas, 3Rd Floor
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10036
Phone16468441164
Websitehttps://oramed.com/
Ticker SymbolORMP
IPO dateApr 01, 2002
CEOKidron (Nadav)
Company Executives of Oramed Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Nadav Kidron
Mr. Nadav Kidron
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.06M
+2.09%
Mr. Benjamin Shapiro
Mr. Benjamin Shapiro
Independent Director
Independent Director
1.93M
-1.56%
Dr. Miriam Kidron, Ph.D.
Dr. Miriam Kidron, Ph.D.
Chief Scientific Officer, Director
Chief Scientific Officer, Director
777.83K
-0.45%
Mr. Avraham Gabay, CPA
Mr. Avraham Gabay, CPA
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
153.01K
+11.41%
Mr. Leonard Sank
Mr. Leonard Sank
Independent Director
Independent Director
30.01K
-70.44%
Mr. Yehuda Reznick
Mr. Yehuda Reznick
Independent Director
Independent Director
19.74K
-63.39%
Dr. Daniel Aghion
Dr. Daniel Aghion
Independent Director
Independent Director
18.82K
-67.09%
Mr. Joshua Hexter
Mr. Joshua Hexter
Chief Operating and Business Officer
Chief Operating and Business Officer
--
--
Dr. Arie Mayer, Ph.D.
Dr. Arie Mayer, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Nadav Kidron
Mr. Nadav Kidron
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.06M
+2.09%
Mr. Benjamin Shapiro
Mr. Benjamin Shapiro
Independent Director
Independent Director
1.93M
-1.56%
Dr. Miriam Kidron, Ph.D.
Dr. Miriam Kidron, Ph.D.
Chief Scientific Officer, Director
Chief Scientific Officer, Director
777.83K
-0.45%
Mr. Avraham Gabay, CPA
Mr. Avraham Gabay, CPA
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
153.01K
+11.41%
Mr. Leonard Sank
Mr. Leonard Sank
Independent Director
Independent Director
30.01K
-70.44%
Mr. Yehuda Reznick
Mr. Yehuda Reznick
Independent Director
Independent Director
19.74K
-63.39%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BML Capital Management LLC
7.96%
Kidron (Nadav)
5.18%
Shapiro (Benjamin)
4.86%
Murchinson Ltd.
4.40%
Boothbay Fund Management, LLC
2.12%
Other
75.47%
Shareholders
Shareholders
Proportion
BML Capital Management LLC
7.96%
Kidron (Nadav)
5.18%
Shapiro (Benjamin)
4.86%
Murchinson Ltd.
4.40%
Boothbay Fund Management, LLC
2.12%
Other
75.47%
Shareholder Types
Shareholders
Proportion
Individual Investor
15.32%
Investment Advisor
8.72%
Investment Advisor/Hedge Fund
7.82%
Research Firm
0.88%
Hedge Fund
0.76%
Venture Capital
0.06%
Other
66.45%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
112
7.28M
18.26%
-1.25M
2025Q2
124
13.94M
34.14%
-901.13K
2025Q1
140
14.12M
34.57%
-1.05M
2024Q4
166
12.68M
31.46%
-741.80K
2024Q3
167
11.86M
29.21%
-291.74K
2024Q2
182
11.21M
27.68%
-1.03M
2024Q1
228
10.28M
25.41%
-3.86M
2023Q4
234
9.69M
24.13%
+273.21K
2023Q3
243
6.84M
17.06%
-2.85M
2023Q2
244
6.81M
17.03%
-4.46M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BML Capital Management LLC
3.08M
7.52%
+62.51K
+2.07%
Jun 30, 2025
Kidron (Nadav)
2.06M
5.03%
+42.18K
+2.09%
Jul 03, 2025
Shapiro (Benjamin)
1.93M
4.72%
-30.66K
-1.56%
Jul 03, 2025
Murchinson Ltd.
1.75M
4.27%
-200.00
-0.01%
Jun 30, 2025
Boothbay Fund Management, LLC
845.39K
2.06%
-97.00
-0.01%
Jun 30, 2025
Hexter Joshua
812.17K
1.98%
+126.83K
+18.51%
Feb 11, 2025
Kidron (Miriam)
777.83K
1.9%
-3.50K
-0.45%
Jul 03, 2025
Rathbones Investment Management Limited
233.02K
0.57%
-3.79K
-1.60%
Jun 30, 2025
Li (Xiaopeng)
218.60K
0.53%
--
--
Jul 03, 2025
Gabay (Avraham)
153.01K
0.37%
+15.67K
+11.41%
Jul 03, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.02%
Dimensional US Core Equity 1 ETF
0%
Avantis US Equity ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
Avantis US Small Cap Equity ETF
0%
SPDR S&P International Small Cap ETF
0%
iShares Micro-Cap ETF
Proportion0.02%
Dimensional US Core Equity 1 ETF
Proportion0%
Avantis US Equity ETF
Proportion0%
SPDR Portfolio Developed World ex-US ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
SPDR S&P International Small Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Oramed Pharmaceuticals Inc?
The top five shareholders of Oramed Pharmaceuticals Inc are:
BML Capital Management LLC holds 3.08M shares, accounting for 7.52% of the total shares.
Kidron (Nadav) holds 2.06M shares, accounting for 5.03% of the total shares.
Shapiro (Benjamin) holds 1.93M shares, accounting for 4.72% of the total shares.
Murchinson Ltd. holds 1.75M shares, accounting for 4.27% of the total shares.
Boothbay Fund Management, LLC holds 845.39K shares, accounting for 2.06% of the total shares.
BML Capital Management LLC holds 3.08M shares, accounting for 7.52% of the total shares.
Kidron (Nadav) holds 2.06M shares, accounting for 5.03% of the total shares.
Shapiro (Benjamin) holds 1.93M shares, accounting for 4.72% of the total shares.
Murchinson Ltd. holds 1.75M shares, accounting for 4.27% of the total shares.
Boothbay Fund Management, LLC holds 845.39K shares, accounting for 2.06% of the total shares.
What are the top three shareholder types of Oramed Pharmaceuticals Inc?
The top three shareholder types of Oramed Pharmaceuticals Inc are:
BML Capital Management LLC
Kidron (Nadav)
Shapiro (Benjamin)
BML Capital Management LLC
Kidron (Nadav)
Shapiro (Benjamin)
How many institutions hold shares of Oramed Pharmaceuticals Inc (ORMP)?
As of 2025Q3, 112 institutions hold shares of Oramed Pharmaceuticals Inc, with a combined market value of approximately 7.28M, accounting for 18.26% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -15.88%.
What is the biggest source of revenue for Oramed Pharmaceuticals Inc?
In --, the -- business generated the highest revenue for Oramed Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
